Europe Cancer Treatment Market Size & Outlook, 2026-2034

Europe Cancer Treatment Market Insights

According to Reed Intelligence analysis, the Europe Cancer Treatment Market size stood at USD 65.39 Billion in 2025 and is forecasted to reach USD 150.76 Billion by 2034.
The market is projected to grow at a CAGR of 9.84% between 2026 and 2034.
By segment, Breast Cancer was the leading By Cancer Type in terms of market size in 2025.
Pancreatic Cancer is expected to be the most lucrative By Cancer Type segment, exhibiting the fastest growth throughout the forecast period.

Other Key Findings

Europe represented 23.17% of the global Cancer Treatment Market size in 2025.
By 2034, United States is estimated to hold the largest position in the global market in terms of size.
France is estimated to remain the fastest-growing market in Europe, advancing to USD 27.94 Billion by 2034.

Report Summary

Report Scope	Details
Base Year for Study	2025
Study Period	2022-2034
Historical Period	2022-2024
Forecast Period	2026-2034
Market Size In 2025	USD 65.39 Billion
Market Size In 2034	USD 150.76 Billion
Largest segment	Breast Cancer
Units	Revenue in USD Billion
CAGR	9.84% (2026-2034)
Segmnetation Covered
Europe	Germany United Kingdom France Italy Spain Russia Nordic Benelux
By Cancer Type	Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Hematologic malignancies Pancreatic Cancer Ovarian Cancer Others
By Product Type	Cytotoxic chemotherapies Monoclonal antibodies Immuno-oncology checkpoint inhibitors Antibody-drug conjugates Cell & gene therapies Others
By End-User	Hospitals and cancer centers Research and academic centers Other
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Europe Cancer Treatment Market Country 2026-2034 (USD Billion)

Europe	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Germany	XX.x	XX.x	XX.x	16.35	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
United Kingdom	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
France	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Italy	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Spain	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Russia	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Nordic	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Benelux	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Cancer Treatment Market By Cancer Type 2026-2034 (USD Billion)

By Cancer Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Breast Cancer	XX.x	XX.x	XX.x	17.32	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Lung Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Colorectal Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Prostate Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Hematologic malignancies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Pancreatic Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Ovarian Cancer	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Cancer Treatment Market By Product Type 2026-2034 (USD Billion)

By Product Type	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Cytotoxic chemotherapies	XX.x	XX.x	XX.x	20.92	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Monoclonal antibodies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Immuno-oncology checkpoint inhibitors	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Antibody-drug conjugates	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Cell & gene therapies	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Others	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Europe Cancer Treatment Market By End-User 2026-2034 (USD Billion)

By End-User	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Hospitals and cancer centers	XX.x	XX.x	XX.x	34.38	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Research and academic centers	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Other	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x
Total	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x	XX.x

Source: RI Analysis Company Publications, Primary Interviews.

Author :

Reed Intelligence Research Team

The Reed Intelligence Research Team brings together over 15+ years of collective experience in market research, data analytics, and strategic consulting. Comprising seasoned analysts, economists, and industry specialists, the team delivers precise, data-driven insights across sectors including technology, healthcare, energy, manufacturing, and consumer goods. By combining domain expertise with modern analytical tools, they ensure each report meets the highest standards of accuracy and relevance.